NovaBridge Biosciences (NBP)

NovaBridge Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	-	-	0.63	-1.55	13.85
Revenue Growth (YoY)	-	-	-	-	-94.14%
Cost of Revenue	-	-	-	-	46.43
Gross Profit	-	-	0.63	-1.55	-32.58
Selling, General & Admin	31.36	29.66	28.16	28.98	141.59
Research & Development	62.91	21.77	21.45	22.55	190.84
Other Operating Expenses	-	-	23.04	-	-
Total Operating Expenses	94.27	51.43	72.65	51.53	332.43
Operating Income	-94.27	-51.43	-72.02	-53.08	-325.89
Interest Income	7.61	6.45	-2.11	-59.75	-54.52
Other Non-Operating Income (Expense)	-1.68	-4.72	-8.09	-28.27	13.08
Total Non-Operating Income (Expense)	5.93	1.73	-10.2	-88.02	-41.44
Pretax Income	-88.34	-49.7	-82.22	-141.1	-367.33
Provision for Income Taxes	-	-	-	-0.1	0.5
Net Income	-46.27	-22.23	-207.73	-371.05	-366.83
Minority Interest in Earnings	-42.07	-	-	-	-
Earnings From Discontinued Operations	-	27.47	-125.51	-229.85	-
Net Income to Common	-46.27	-22.23	-207.73	-371.05	-366.83
Shares Outstanding (Basic)	96	81	83	83	76
Shares Outstanding (Diluted)	96	81	83	83	76
Shares Change (YoY)	17.96%	-2.45%	0.86%	8.63%	11.11%
EPS (Basic)	-0.48	-0.28	-2.51	-4.51	-4.83
EPS (Diluted)	-0.48	-0.28	-2.51	-4.51	-4.83
Shares Outstanding	115.38	81.5	80.7	82.99	79.92
Free Cash Flow	-20.6	-52.72	-72.86	-51.67	-157.81
Free Cash Flow Per Share	-0.22	-0.65	-0.88	-0.63	-2.08
Gross Margin	-	-	100.00%	100.00%	-235.26%
Operating Margin	-	-	-11395.10%	3422.18%	-2353.06%
Profit Margin	-	-	-13009.00%	9104.00%	-2655.86%
FCF Margin	-	-	-11528.60%	3331.59%	-1139.46%
EBITDA	-94.2	-51.17	-71.54	-52.87	-323.6
EBITDA Margin	-	-	-11319.90%	3408.90%	-2336.53%
EBIT	-94.27	-51.43	-72.02	-53.08	-325.89
EBIT Margin	-	-	-11395.10%	3422.18%	-2353.06%
Effective Tax Rate	0.00%	0.00%	0.00%	0.07%	-0.14%

Updated Apr 8, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q